GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium
Issued: Thursday 08 December 2011, London, UK - Improvement in disease-free survival does not reach statistical significance in study of delayed adjuvant therapy with lapatinib (Tykerb or Tyverb) monotherapy in HER2 positive breast cancer. Results from …